Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint

被引:94
|
作者
Duffull, Stephen B. [1 ]
Wright, Daniel F. B. [1 ]
Winter, Helen R. [1 ,2 ]
机构
[1] Univ Otago, Sch Pharm, Dunedin 9054, New Zealand
[2] Global Alliance TB Drug Dev, New York, NY 10005 USA
关键词
pharmacodynamics; pharmacokinetics; pharmacometrics; population analyses; statistical models; CYSTIC-FIBROSIS PATIENTS; DRUG DEVELOPMENT; DOSING STRATEGY; RENAL-FUNCTION; MODEL; ENOXAPARIN; PARAMETERS; DESIGN; ITRACONAZOLE; SIMULATION;
D O I
10.1111/j.1365-2125.2010.03891.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The population analysis approach is an important tool for clinical pharmacology in aiding the dose individualization of medicines. However, due to their statistical complexity the clinical utility of population analyses is often overlooked. One of the key reasons to conduct a population analysis is to investigate the potential benefits of individualization of drug dosing based on patient characteristics (termed covariate identification). The purpose of this review is to provide a tool to interpret and extract information from publications that describe population analysis. The target audience is those readers who are aware of population analyses but have not conducted the technical aspects of an analysis themselves. Initially we introduce the general framework of population analysis and work through a simple example with visual plots. We then follow-up with specific details on how to interpret population analyses for the purpose of identifying covariates and how to interpret their likely importance for dose individualization.
引用
收藏
页码:807 / 814
页数:8
相关论文
共 50 条
  • [21] Population Pharmacokinetic-Pharmacodynamic Modeling of Ropivacaine in Spinal Anesthesia
    Zoubir Djerada
    Catherine Feliu
    Yoann Cazaubon
    Faouzi Smati
    Philippe Gomis
    Dominique Guerrot
    Beny Charbit
    Olivier Fernandes
    Jean-Marc Malinovsky
    Clinical Pharmacokinetics, 2018, 57 : 1135 - 1147
  • [22] A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide
    Phillips, L
    Grasela, TH
    Agnew, JR
    Ludwig, EA
    Thompson, GA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (04) : 370 - 383
  • [23] Population pharmacokinetic-pharmacodynamic modeling of spinal anesthesia with ropivacaine
    Djerada, Z.
    Feliu, C.
    Cazaubon, Y.
    Smati, F.
    Gomis, P.
    Charbit, B.
    Fernandes, O.
    Malinovsky, J. M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 18 - 18
  • [24] A Population Pharmacokinetic-Pharmacodynamic Model for Allopurinol in Patients with Gout
    Wright, Daniel F. B.
    Duffull, Stephen B.
    Merriman, Tony R.
    Barclay, Murray L.
    Stamp, Lisa K.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S33 - S33
  • [25] Population Pharmacokinetic-Pharmacodynamic Modeling of Ropivacaine in Spinal Anesthesia
    Djerada, Zoubir
    Feliu, Catherine
    Cazaubon, Yoann
    Smati, Faouzi
    Gomis, Philippe
    Guerrot, Dominique
    Charbit, Beny
    Fernandes, Olivier
    Malinovsky, Jean-Marc
    CLINICAL PHARMACOKINETICS, 2018, 57 (09) : 1135 - 1147
  • [26] Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments
    Andrew Hooker
    Paolo Vicini
    The AAPS Journal, 7
  • [27] Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process - Experience at Parke-Davis
    Olson, SC
    Bockbrader, H
    Boyd, RA
    Cook, J
    Koup, JR
    Lalonde, RL
    Siedlik, PH
    Powell, JR
    CLINICAL PHARMACOKINETICS, 2000, 38 (05) : 449 - 459
  • [28] In Silico Assessment of Nifedipine Effects on Human Heart Cells: Pharmacokinetic-Pharmacodynamic Analyses at the Population Level
    Abbasi, Mitra
    Polak, Sebastian
    2017 COMPUTING IN CARDIOLOGY (CINC), 2017, 44
  • [29] Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis
    Kloprogge, Frank
    Mwandumba, Henry C.
    Banda, Gertrude
    Kamdolozi, Mercy
    Shani, Doris
    Corbett, Elizabeth L.
    Kontogianni, Nadia
    Ward, Steve
    Khoo, Saye H.
    Davies, Geraint R.
    Sloan, Derek J.
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (07):
  • [30] Dose optimisation in clinical oncology: Pharmacokinetic-pharmacodynamic relationships
    Canal, P
    Chatelut, E
    BULLETIN DU CANCER, 1996, 83 (04) : 256 - 265